Kim A. Reiss Binder, MD, assistant professor of medicine in the Division of Hematology Oncology at the University of Pennsylvania, discusses data on maintenance therapy with rucaparib (Rubraca) in patients with pancreatic cancer.
Early, interim data from a study that examined rucaparib maintenance among patients with platinum-sensitive, advanced BRCA1/2– or PALB2-mutant pancreatic cancer showed that it was very well tolerated, says Binder. The majority of side effects were grade 1, and there were no dose-limiting toxicities. Though, 1 patient was dose-reduced as a result of grade 2 nausea, says Binder. Encouragingly, no grade 3/4 adverse events were reported in the cohort. Watch here . . .